CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)

BACKGROUND: The third‐generation EGFR‐TKI, represented by osimertinib, has been widely used in clinical practice; however, resistance eventually emerges. At present, it remains unclear whether an abnormal cell cycle is involved in acquired resistance, and whether the combination of palbociclib (CDK4...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qiong, Li, Xiaoqing, Liang, Xingmei, Zeng, Lili, Wang, Jing, Sun, Linlin, Zhong, Diansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471056/
https://www.ncbi.nlm.nih.gov/pubmed/32677256
http://dx.doi.org/10.1111/1759-7714.13521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471056/
https://www.ncbi.nlm.nih.gov/pubmed/32677256
http://dx.doi.org/10.1111/1759-7714.13521

Ejemplares similares